We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$171M
AUM Growth
+$11.3M
Cap. Flow
-$9.27M
Cap. Flow %
-5.41%
Top 10 Hldgs %
62.79%
Holding
42
New
12
Increased
7
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$5.19M
2
XRAY icon
Dentsply Sirona
XRAY
+$4.86M
3
MDT icon
Medtronic
MDT
+$3.79M
4
MDRX
Veradigm Inc. Common Stock
MDRX
+$3.46M
5
LH icon
Labcorp
LH
+$2.85M

Top Sells

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$7.63M
2
BSX icon
Boston Scientific
BSX
+$5.31M
3
ATHN
Athenahealth, Inc.
ATHN
+$3.38M
4
WBA
Walgreens Boots Alliance
WBA
+$3.29M
5
ALKS icon
Alkermes
ALKS
+$2.9M

Sector Composition

Rank Sector Weight
1 Healthcare 94.86%
2 Industrials 3.22%
3 Consumer Discretionary 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCM
26
DELISTED
R1 RCM Inc. Common Stock
RCM
$938K 0.55%
250,000
-7,400
-3% -$27.2K
OEF icon
27
PUT
iShares S&P 100 ETF
OEF
$20.1B
$690K 0.4%
+2,000
New +$213K
SPY icon
28
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$326K 0.19%
+4,000
New +$959K
KO icon
29
PUT
Coca-Cola
KO
$377B
$134K 0.08%
+1,000
New +$44.2K
BKD icon
30
CALL
Brookdale Senior Living
BKD
$3.49B
$106K 0.06%
+2,000
New +$27.6K
SPNC
31
CALL
DELISTED
Spectranetics Corp
SPNC
$89K 0.05%
+7,752
New +$224K
BSX icon
32
PUT
Boston Scientific
BSX
$69.5B
$55K 0.03%
+886
New +$23.5K
DGX icon
33
PUT
Quest Diagnostics
DGX
$25.7B
$39K 0.02%
+376
New +$39.8K
PDCO
34
PUT
DELISTED
Patterson Companies, Inc.
PDCO
$4K ﹤0.01%
+300
New +$13.5K
AMGN icon
35
Amgen
AMGN
$208B
– –
-130
Closed -$2K
BSX icon
36
Boston Scientific
BSX
$69.5B
– –
-200,000
Closed -$5.31M
TDOC icon
37
Teladoc Health
TDOC
$1.22B
– –
-305,000
Closed -$7.63M
NVRO
38
DELISTED
NEVRO CORP.
NVRO
– –
-17,100
Closed -$1.6M
QTNT
39
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-1,250
Closed -$350K
AKRX
40
DELISTED
Akorn Inc
AKRX
– –
-70,969
Closed -$1.71M
ATHN
41
DELISTED
Athenahealth, Inc.
ATHN
– –
-30,000
Closed -$3.38M
ENTL
42
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
– –
-45,837
Closed -$633K
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q2 2017 Portfolio in Review

As of Q2 2017, Tamarack Advisers held 42 positions worth $171M, up 7% from $160M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Tamarack Advisers withdrew a net $9.27M in Q2 2017, closing 8 positions and reducing 13 holdings. Its most notable exit was Teladoc Health, an estimated $7.63M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Industrials and Consumer Discretionary.

Against the trend, Tamarack Advisers opened a new position in Tivity Health, Inc. Common Stock worth $6.18M.

  • Tamarack Advisers's largest Q2 2017 buy was Tivity Health, Inc. Common Stock: 155,215 shares worth $6.18M.
  • Tamarack Advisers added most to Veradigm Inc. Common Stock in Q2 2017, an estimated $3.46M increase.
  • Tamarack Advisers's biggest Q2 2017 reduction was Walgreens Boots Alliance, cutting an estimated $3.29M.
  • Tamarack Advisers fully exited Teladoc Health in Q2 2017, selling an estimated $7.63M.
  • Tamarack Advisers's ten largest holdings make up 63% of its $171M portfolio in Q2 2017.
  • Tamarack Advisers opened 12 new positions and closed 8 in Q2 2017.
  • Tamarack Advisers's portfolio value rose 7% quarter-over-quarter to $171M.

Based on Tamarack Advisers's 13F filing for Q2 2017, filed 8 Aug 2017.